Actively Recruiting
Phase 2 Study of Oral XL092 for Treating Advanced or Spread Differentiated Thyroid Cancer Not Responding to Radioiodine
Led by Jochen Lorch · Updated on 2026-06-26
33
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating XL092, a tyrosine kinase inhibitor, for treating patients with differentiated thyroid cancer that is resistant to previous radioiodine treatment and has spread locally or to other parts of the body. This phase II trial aims to assess how well XL092 controls the disease by measuring the proportion of patients alive without progression at 12 months, as well as overall survival, progression-free survival, safety, and quality of life. The study also explores immune response and genetic markers related to treatment success or failure. Participants receive oral XL092 daily for 21 days in each 21-day cycle, continuing until disease progression or unacceptable side effects occur. During treatment, patients undergo CT or MRI scans, x-ray imaging, and blood and urine sample collections. After finishing treatment, participants have follow-up visits at 30 days and then every 3 months for up to 12 months to monitor their health and disease status. Throughout the study, researchers evaluate disease progression using imaging and track overall survival and quality of life changes. They monitor safety by recording adverse events up to 30 days after treatment ends. Participants also provide biological samples for immune and genetic studies. The total participation duration includes treatment cycles plus one year of follow-up after treatment completion.
CONDITIONS
Brief Title
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here